OVERVIEW

PT-141 (Bremelanotide) is a synthetic peptide derived from melanocortin receptor research and is known for its role in modulating sexual desire pathways in the brain. Unlike medications that primarily affect blood flow, PT-141 works centrally by activating melanocortin receptors, particularly MC4R, which are involved in sexual arousal and motivation. It was originally investigated as a tanning agent derivative but later developed for its effects on libido. Bremelanotide has received regulatory approval in certain countries for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women under specific brand names and prescribed dosing guidelines.

A package containing 3mg x 10 vials (total 30mg) typically reflects a multi-dose supply format. In approved medical use, PT-141 is administered via subcutaneous injection prior to anticipated sexual activity, following strict dosing recommendations. Common side effects reported in clinical settings include nausea, flushing, headache, and temporary increases in blood pressure. Because it acts on central nervous system pathways and can influence cardiovascular parameters, medical screening and supervision are important. PT-141 should only be used under the guidance of a qualified healthcare professional, particularly for individuals with underlying cardiovascular conditions or those taking medications that may interact with melanocortin receptor activity.